UBS Reiterates a 'Buy' on Heartware Int'l (HTWR); Very Positive Outcome
Tweet Send to a FriendGet Alerts HTWR Hot Sheet
Price: $99.19 +3.93%
Rating Summary:
7 Buy, 9 Hold, 4 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
7 Buy, 9 Hold, 4 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade HTWR Now!
UBS reiterates a 'Buy' on Heartware Int'l (NASDAQ: HTWR) price target raised from $95 to $110.
Analyst, Rajeev Jashnani, said, "Summary of panel votes: safety 8-3 in favor of HVAD; efficacy 11-0 in favor of HVAD; risk/benefit 9-2 in favor of HVAD. Votes were overwhelmingly positive. Panelists seemed comfortable w/ ischemic stroke & pump thrombosis, key concerns related to trial execution, primarily CEC issues (this is the group that adjudicates AE's; composition changed over course of trial & some procedures were called into question). Panel wanted to see safety from INTERMACS control group, but this concern seems misplaced given self-reporting w/ that database."
Jashnani noted that approval may not be right around the corner (may be up to several months), but FDA sintering data should be straightforward and UBS is hopeful for a quick approval.
For an analyst ratings summary and ratings history on Heartware Int'l click here. For more ratings news on Heartware Int'l click here.
Shares of Heartware Int'l closed at $69.27 yesterday, with a 52 week range of $53.40-$79.91.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Rajeev Jashnani, said, "Summary of panel votes: safety 8-3 in favor of HVAD; efficacy 11-0 in favor of HVAD; risk/benefit 9-2 in favor of HVAD. Votes were overwhelmingly positive. Panelists seemed comfortable w/ ischemic stroke & pump thrombosis, key concerns related to trial execution, primarily CEC issues (this is the group that adjudicates AE's; composition changed over course of trial & some procedures were called into question). Panel wanted to see safety from INTERMACS control group, but this concern seems misplaced given self-reporting w/ that database."
Jashnani noted that approval may not be right around the corner (may be up to several months), but FDA sintering data should be straightforward and UBS is hopeful for a quick approval.
For an analyst ratings summary and ratings history on Heartware Int'l click here. For more ratings news on Heartware Int'l click here.
Shares of Heartware Int'l closed at $69.27 yesterday, with a 52 week range of $53.40-$79.91.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
- UPDATE: Vanda Pharmaceuticals (VNDA) Opens Higher; Lazard Raises PT to $17
- Deutsche Bank Takes Aegerion (AEGR) Price Target from $52 to $85
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
UBS
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
